Medidata Medidata

Behind the ADAPTABLE Study, the Largest Decentralized Clinical Trial to Date Reg

Downloadable

[Case Study] Behind the ADAPTABLE Study, the Largest Decentralized Clinical Trial to Date

For over half a century, millions of Americans living with heart disease have relied on a daily dose of aspirin to help prevent a heart attack or stroke. The most commonly prescribed dosages are 81 mg and 325 mg. The goal of the
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness) study is to determine the dosage that most effectively maximizes results while minimizing harmful side effects such as internal bleeding. The study is led by researchers at the Duke Clinical Research Institute (DCRI), the world’s largest academic clinical research organization and a part of the Duke School of Medicine.

“When compared with traditional cardiovascular trials that engage hundreds or thousands of sites, this technology allowed us to enroll 15,000 participants from 40 centers.”

Dr. Schuyler Jones, Associate Professor of Medicine
Duke University Medical Center